TEMOVATE E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TEMOVATE E (TEMOVATE E).
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Mildly absorbed percutaneously; metabolized in the liver via CYP3A4; excreted renally and biliary. |
| Excretion | Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for a minor fraction. |
| Half-life | Terminal elimination half-life: approximately 1.5-3 hours (topical application). Clobetasol propionate is rapidly cleared, minimizing systemic accumulation with short-term use. |
| Protein binding | Approximately 96-99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Not well characterized for topical formulation; estimated Vd ~0.5 L/kg based on systemic absorption data. Reflects distribution into extracellular fluid and tissues. |
| Bioavailability | Topical: Low systemic bioavailability (~1-7%) due to high potency and limited percutaneous absorption; enhanced by occlusion or damaged skin. |
| Onset of Action | Topical: Improvement may be noted within 2-3 days of twice-daily application, with measurable vasoconstriction as early as 2-4 hours. |
| Duration of Action | Therapeutic effect lasts 12-24 hours after single application, supporting twice-daily dosing. Continued treatment for up to 2 consecutive weeks is recommended for chronic conditions. |
Apply a thin layer to the affected skin areas once daily. Not for use for more than 2 consecutive weeks. Use no more than 50 g per week. Not for use in children under 12 years.
| Dosage form | CREAM |
| Renal impairment | No specific dosing adjustment required for renal impairment. Use with caution in patients with severe renal impairment due to possible systemic absorption. |
| Liver impairment | No specific dosing adjustment required for hepatic impairment. However, due to potential for systemic absorption, caution is advised in patients with severe hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients under 12 years due to higher risk of HPA axis suppression. For children 12 years and older, use same as adult dosing but limit to shortest duration possible, typically no more than 2 weeks. |
| Geriatric use | No specific dose adjustment needed. Use with caution due to increased likelihood of skin thinning and systemic absorption. Limit use to shortest duration possible and avoid occlusive dressings. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TEMOVATE E (TEMOVATE E).
| Breastfeeding | It is not known whether topical clobetasol propionate is excreted in human milk. Systemic absorption after topical application is minimal, but caution should be exercised. Use only if clearly needed. M/P ratio not available; limited data suggest negligible levels in milk. |
| Teratogenic Risk | Topical corticosteroids like TEMOVATE E (clobetasol propionate) are classified as Pregnancy Category C. Animal studies have shown teratogenicity with topical corticosteroids, but there are no adequate and well-controlled studies in pregnant women. Systemic absorption after topical application is low; however, risks cannot be excluded. Use only if potential benefit justifies risk to fetus. First trimester: avoid unless necessary. Second and third trimesters: use lowest potency for shortest duration. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Hypersensitivity to clobetasol propionate or any component; infections (e.g., tuberculosis, fungal, bacterial, viral) at treatment site; use in children <12 years (safety not established).
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and unmask latent diabetes; avoid use on face, groin, axillae, or intertriginous areas; do not use with occlusive dressings; local irritation and atrophy possible. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in the mother if large areas are treated or occlusive dressings used. In fetus/newborn, watch for potential adrenal suppression if prolonged maternal use. No specific fetal monitoring required with brief, limited topical use. |
| Fertility Effects | No human studies on fertility effects. Animal studies with topical corticosteroids have shown no impairment of fertility at low systemic doses. Systemic absorption from topical use is minimal, so effects on fertility are expected to be negligible. |